K. Tarte, F. Zhan, D. Vos, J. Klein, B. Shaughnessy et al., Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation, Blood, vol.102, issue.2, pp.592-600, 2003.
DOI : 10.1182/blood-2002-10-3161

J. Piskurich, K. Lin, Y. Lin, Y. Wang, J. Ting et al., BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells, Nature Immunology, vol.1, issue.6, pp.526-558, 2000.
DOI : 10.1038/82788

M. Shapiro-shelef, K. Lin, L. Mcheyzer-williams, J. Liao, M. Mcheyzer-williams et al., Blimp-1 Is Required for the Formation of Immunoglobulin Secreting Plasma Cells and Pre-Plasma Memory B Cells, Immunity, vol.19, issue.4, pp.607-627, 2003.
DOI : 10.1016/S1074-7613(03)00267-X

A. Shaffer, K. Lin, T. Kuo, X. Yu, E. Hurt et al., Blimp-1 Orchestrates Plasma Cell Differentiation by Extinguishing the Mature B Cell Gene Expression Program, Immunity, vol.17, issue.1, pp.51-62, 2002.
DOI : 10.1016/S1074-7613(02)00335-7

Y. Lin, K. Wong, and K. Calame, Repression of c-myc Transcription by Blimp-1, an Inducer of Terminal B Cell Differentiation, Science, vol.276, issue.5312, pp.596-605, 1997.
DOI : 10.1126/science.276.5312.596

A. Shaffer, X. Yu, Y. He, J. Boldrick, E. Chan et al., BCL-6 Represses Genes that Function in Lymphocyte Differentiation, Inflammation, and Cell Cycle Control, Immunity, vol.13, issue.2, pp.199-212, 2000.
DOI : 10.1016/S1074-7613(00)00020-0

R. Phan and R. Dalla-favera, The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells, Nature, vol.82, issue.7017, pp.635-644, 2004.
DOI : 10.1038/ng1018

N. Fujita, D. Jaye, C. Geigerman, A. Akyildiz, M. Mooney et al., MTA3 and the Mi-2/NuRD Complex Regulate Cell Fate during B Lymphocyte Differentiation, Cell, vol.119, issue.1, pp.75-86, 2004.
DOI : 10.1016/j.cell.2004.09.014

K. Lin, C. Angelin-duclos, T. Kuo, and K. Calame, Blimp-1-Dependent Repression of Pax-5 Is Required for Differentiation of B Cells to Immunoglobulin M-Secreting Plasma Cells, Molecular and Cellular Biology, vol.22, issue.13, pp.4771-80, 2002.
DOI : 10.1128/MCB.22.13.4771-4780.2002

A. Muto, H. Hoshino, L. Madisen, N. Yanai, M. Obinata et al., Identification of Bach2 as a B-cell-specific partner for small Maf proteins that negatively regulate the immunoglobulin heavy chain gene 3' enhancer, The EMBO Journal, vol.17, issue.19, pp.5734-5777, 1998.
DOI : 10.1093/emboj/17.19.5734

H. Lin and R. Grosschedl, Failure of B-cell differentiation in mice lacking the transcription factor EBF, Nature, vol.376, issue.6537, pp.263-270, 1995.
DOI : 10.1038/376263a0

H. Mittrucker, T. Matsuyama, A. Grossman, T. Kundig, J. Potter et al., Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function, Science, vol.275, issue.5299, pp.540-543, 1997.
DOI : 10.1126/science.275.5299.540

L. Corcoran, J. Hasbold, W. Dietrich, E. Hawkins, A. Kallies et al., Differential requirement for OBF-1 during antibody-secreting cell differentiation, The Journal of Experimental Medicine, vol.58, issue.9, pp.1385-96, 2005.
DOI : 10.1023/A:1009843325770

S. Honma, T. Kawamoto, Y. Takagi, K. Fujimoto, F. Sato et al., Dec1 and Dec2 are regulators of the mammalian molecular clock, Nature, vol.20, issue.6909, pp.841-845, 2002.
DOI : 10.1074/jbc.274.10.6043

K. Tarte, D. Vos, J. Thykjaer, T. Zhan, F. Fiol et al., Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts, Blood, vol.100, pp.1113-1135, 2002.

C. Pellat-deceunynck and R. Bataille, Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression, Blood Cells, Molecules, and Diseases, vol.32, issue.2, pp.293-301, 2004.
DOI : 10.1016/j.bcmd.2003.12.001

N. Robillard, C. Pellat-deceunynck, and R. Bataille, Phenotypic characterization of the human myeloma cell growth fraction, Blood, vol.105, issue.12, pp.4845-4853, 2005.
DOI : 10.1182/blood-2004-12-4700

L. Terstappen, J. Steen, M. Seger-nolten, and M. Loken, Identification and characterization of plasma cells in normal bone marrow by high resolution flow cytometry, pp.1739-1747, 1990.

M. Mahmoud, H. Ishikawa, R. Fujii, and M. Kawano, Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6, Blood, vol.92, pp.3887-97, 1998.

F. Medina, C. Segundo, and J. Brieva, Purification of human tonsil plasma cells: Pre-enrichment step by immunomagnetic selection of CD31+ cells, Cytometry, vol.32, issue.3, pp.231-235, 2000.
DOI : 10.1002/(SICI)1097-0320(20000301)39:3<231::AID-CYTO9>3.0.CO;2-G

F. Zhan, J. Hardin, K. Bumm, M. Zheng, E. Tian et al., Molecular Profiling of Newly Diagnosed Multiple Myeloma, Blood, vol.98, p.733, 2001.

M. Odendahl, H. Mei, B. Hoyer, A. Jacobi, A. Hansen et al., Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response, Blood, vol.105, issue.4, pp.1614-1635, 2005.
DOI : 10.1182/blood-2004-07-2507

E. Kunkel and E. Butcher, Plasma-cell homing, Nature Reviews Immunology, vol.3, issue.10, pp.822-831, 2003.
DOI : 10.1038/nri1203

Q. Ma, D. Jones, and T. Springer, The Chemokine Receptor CXCR4 Is Required for the Retention of B Lineage and Granulocytic Precursors within the Bone Marrow Microenvironment, Immunity, vol.10, issue.4, pp.463-71, 1999.
DOI : 10.1016/S1074-7613(00)80046-1

D. Hargreaves, P. Hyman, T. Lu, V. Ngo, A. Bidgol et al., A Coordinated Change in Chemokine Responsiveness Guides Plasma Cell Movements, The Journal of Experimental Medicine, vol.95, issue.1, pp.45-56, 2001.
DOI : 10.4049/jimmunol.165.6.3423

J. Cyster, Chemokines and Cell Migration in Secondary Lymphoid Organs, Science, vol.286, issue.5447, pp.2098-102, 1999.
DOI : 10.1126/science.286.5447.2098

D. Vos, J. Couderc, G. Tarte, K. Jourdan, M. Requirand et al., Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays, Blood, vol.98, issue.3, pp.771-780, 2001.
DOI : 10.1182/blood.V98.3.771

G. Wright, B. Tan, A. Rosenwald, E. Hurt, A. Wiestner et al., A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma, Proceedings of the National Academy of Sciences, vol.97, issue.26, pp.9991-9997, 2003.
DOI : 10.1073/pnas.211566398

M. Kopf, H. Baumann, G. Freer, M. Freudenberg, M. Lamers et al., Impaired immune and acute-phase responses in interleukin-6-deficient mice, Nature, vol.368, issue.6469, pp.339-342, 1994.
DOI : 10.1038/368339a0

S. Suematsu, T. Matsuda, K. Aozasa, S. Akira, N. Nakano et al., IgG1 plasmacytosis in interleukin 6 transgenic mice., Proceedings of the National Academy of Sciences, vol.86, issue.19, pp.7547-7551, 1989.
DOI : 10.1073/pnas.86.19.7547

G. Jego, R. Bataille, and C. Pellat-deceunynck, Interleukin-6 is a growth factor for nonmalignant human plasmablasts, Blood, vol.97, issue.6, pp.1817-1839, 2001.
DOI : 10.1182/blood.V97.6.1817

S. Seidl, H. Kaufmann, and J. Drach, New insights into the pathophysiology of multiple myeloma, The Lancet Oncology, vol.4, issue.9, pp.557-64, 2003.
DOI : 10.1016/S1470-2045(03)01195-1

C. Logan and R. Nusse, THE WNT SIGNALING PATHWAY IN DEVELOPMENT AND DISEASE, Annual Review of Cell and Developmental Biology, vol.20, issue.1, pp.781-810, 2004.
DOI : 10.1146/annurev.cellbio.20.010403.113126

J. Han, S. Choi, N. Kurihara, M. Koide, Y. Oba et al., Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand, Blood, vol.97, issue.11, pp.3349-53, 2001.
DOI : 10.1182/blood.V97.11.3349

J. Claudio, E. Masih-khan, H. Tang, J. Goncalves, M. Voralia et al., A molecular compendium of genes expressed in multiple myeloma, Blood, vol.100, issue.6, pp.2175-86, 2002.
DOI : 10.1182/blood-2002-01-0008

U. Salzer, H. Chapel, A. Webster, Q. Pan-hammarstrom, A. Schmitt-graeff et al., Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans, Nature Genetics, vol.53, issue.8, pp.820-828, 2005.
DOI : 10.1038/ng1600

F. Mackay, P. Schneider, P. Rennert, and J. Browning, APRIL: A Tutorial on B Cell Survival, Annual Review of Immunology, vol.21, issue.1, pp.231-64, 2003.
DOI : 10.1146/annurev.immunol.21.120601.141152

O. Connor, B. Raman, V. Erickson, L. Cook, W. Weaver et al., BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells, The Journal of Experimental Medicine, vol.157, issue.1, pp.91-99, 2004.
DOI : 10.1038/nsb769

L. Ng, C. Mackay, and F. Mackay, The BAFF/APRIL system: life beyond B lymphocytes, Molecular Immunology, vol.42, issue.7, pp.763-72, 2005.
DOI : 10.1016/j.molimm.2004.06.041

J. Moreaux, F. Cremer, T. Reme, M. Raab, K. Mahtouk et al., The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature, Blood, vol.106, issue.3, 2005.
DOI : 10.1182/blood-2004-11-4512

URL : https://hal.archives-ouvertes.fr/inserm-00129406

K. Ingold, A. Zumsteg, A. Tardivel, B. Huard, Q. Steiner et al., Identification of proteoglycans as the APRIL-specific binding partners, The Journal of Experimental Medicine, vol.103, issue.9, pp.1375-83, 2005.
DOI : 10.1002/eji.1830221136

V. Costes, V. Magen, E. Legouffe, L. Durand, P. Baldet et al., The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens, Human Pathology, vol.30, issue.12, pp.1405-1416, 1999.
DOI : 10.1016/S0046-8177(99)90160-0

C. Volpe, A. Lundgren, A. Aints, A. Mohamed, P. Jaakkola et al., Proximal promoter of the murine syndecan-1 gene is not sufficient for the developmental pattern of syndecan expression in B lineage cells, American Journal of Hematology, vol.272, issue.1, pp.20-26, 2001.
DOI : 10.1002/ajh.1071

R. Sun, Z. Lu, J. Wijdenes, J. Brochier, C. Hertog et al., Large scale and clinical grade purification of syndecan-1+ malignant plasma cells, Journal of Immunological Methods, vol.205, issue.1, pp.73-79, 1997.
DOI : 10.1016/S0022-1759(97)00056-2

M. Bernfield, M. Gotte, P. Park, O. Reizes, M. Fitzgerald et al., Functions of Cell Surface Heparan Sulfate Proteoglycans, Annual Review of Biochemistry, vol.68, issue.1, pp.729-77, 1999.
DOI : 10.1146/annurev.biochem.68.1.729

M. Borset, O. Hjertner, S. Yaccoby, J. Epstein, and R. Sanderson, Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins, Blood, vol.96, pp.2528-2564, 2000.

Q. Lu, M. Gore, Q. Zhang, T. Camenisch, S. Boast et al., Tyro-3 family receptors are essential regulators of mammalian spermatogenesis, Nature, vol.398, pp.723-731, 1999.

M. Katagiri, Y. Hakeda, D. Chikazu, T. Ogasawara, T. Takato et al., Mechanism of Stimulation of Osteoclastic Bone Resorption through Gas6/Tyro 3, a Receptor Tyrosine Kinase Signaling, in Mouse Osteoclasts, Journal of Biological Chemistry, vol.276, issue.10, pp.7376-82, 2001.
DOI : 10.1074/jbc.M007393200

Q. Lu and G. Lemke, Homeostatic Regulation of the Immune System by Receptor Tyrosine Kinases of the Tyro 3 Family, Science, vol.293, issue.5528, pp.306-317, 2001.
DOI : 10.1126/science.1061663

A. Angelillo-scherrer, P. De-frutos, C. Aparicio, E. Melis, P. Savi et al., Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis, Nature Medicine, vol.7, issue.2, pp.215-236, 2001.
DOI : 10.1038/84667

Z. Lan, H. Wu, W. Li, S. Wu, L. Lu et al., Transforming activity of receptor tyrosine kinase tyro3 is mediated, at least in part, by the PI3 kinase-signaling pathway, Blood, vol.95, pp.633-641, 2000.

P. Van-ginkel, R. Gee, R. Shearer, L. Subramanian, T. Walker et al., Expression of the Receptor Tyrosine Kinase Axl Promotes Ocular Melanoma Cell Survival, Cancer Research, vol.64, issue.1, pp.128-162, 2004.
DOI : 10.1158/0008-5472.CAN-03-0245

H. Yoshida, T. Matsui, A. Yamamoto, T. Okada, and K. Mori, XBP1 mRNA Is Induced by ATF6 and Spliced by IRE1 in Response to ER Stress to Produce a Highly Active Transcription Factor, Cell, vol.107, issue.7, pp.881-91, 2001.
DOI : 10.1016/S0092-8674(01)00611-0

A. Reimold, N. Iwakoshi, J. Manis, P. Vallabhajosyula, E. Szomolanyi-tsuda et al., Plasma cell differentiation requires the transcription factor XBP- 1, Nature, vol.412, issue.6844, pp.300-307, 2001.
DOI : 10.1038/35085509

N. Iwakoshi, A. Lee, P. Vallabhajosyula, K. Otipoby, K. Rajewsky et al., Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1, Nature Immunology, vol.4, issue.4, pp.321-330, 2003.
DOI : 10.1038/ni907

A. Shaffer, M. Shapiro-shelef, N. Iwakoshi, A. Lee, S. Qian et al., XBP1, Downstream of Blimp-1, Expands the Secretory Apparatus and Other Organelles, and Increases Protein Synthesis in Plasma Cell Differentiation, Immunity, vol.21, issue.1, pp.81-93, 2004.
DOI : 10.1016/j.immuni.2004.06.010

A. Lee, N. Iwakoshi, and L. Glimcher, XBP-1 Regulates a Subset of Endoplasmic Reticulum Resident Chaperone Genes in the Unfolded Protein Response, Molecular and Cellular Biology, vol.23, issue.21, pp.7448-59, 2003.
DOI : 10.1128/MCB.23.21.7448-7459.2003

S. Marciniak, C. Yun, S. Oyadomari, I. Novoa, Y. Zhang et al., CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum, Genes & Development, vol.18, issue.24, pp.3066-77, 2004.
DOI : 10.1101/gad.1250704

M. Bakkus, C. Heirman, I. Van-riet, V. Camp, B. Thielemans et al., Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation, Blood, vol.80, pp.2326-2335, 1992.

J. Harousseau, P. Moreau, M. Attal, T. Facon, and H. Avet-loiseau, Stem-cell transplantation in multiple myeloma, Best Practice & Research Clinical Haematology, vol.18, issue.4, pp.603-621, 2005.
DOI : 10.1016/j.beha.2005.01.005

S. Singhal, J. Mehta, R. Desikan, D. Ayers, P. Roberson et al., Antitumor Activity of Thalidomide in Refractory Multiple Myeloma, New England Journal of Medicine, vol.341, issue.21, pp.1565-71, 1999.
DOI : 10.1056/NEJM199911183412102

P. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath et al., A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma, New England Journal of Medicine, vol.348, issue.26, pp.2609-2626, 2003.
DOI : 10.1056/NEJMoa030288

M. Cavo, E. Zamagni, P. Tosi, P. Tacchetti, C. Cellini et al., Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma, Blood, vol.106, issue.1, pp.35-44, 2005.
DOI : 10.1182/blood-2005-02-0522

R. Kyle, T. Therneau, S. Rajkumar, J. Offord, D. Larson et al., A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance, New England Journal of Medicine, vol.346, issue.8, pp.564-573, 2002.
DOI : 10.1056/NEJMoa01133202

R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. Bergsagel et al., Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report, Cancer Research, vol.64, issue.4, pp.1546-58, 2004.
DOI : 10.1158/0008-5472.CAN-03-2876

G. Pratt, Molecular aspects of multiple myeloma, Molecular Pathology, vol.55, issue.5, pp.273-83, 2002.
DOI : 10.1136/mp.55.5.273

N. Smadja, C. Bastard, C. Brigaudeau, D. Leroux, and C. Fruchart, Hypodiploidy is a major prognostic factor in multiple myeloma, Blood, vol.98, issue.7, pp.2229-2267, 2001.
DOI : 10.1182/blood.V98.7.2229

N. Smadja, D. Leroux, J. Soulier, S. Dumont, C. Arnould et al., Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases, Genes, Chromosomes and Cancer, vol.98, issue.3, pp.234-243, 2003.
DOI : 10.1002/gcc.10275

R. Fonseca, C. Debes-marun, E. Picken, G. Dewald, S. Bryant et al., The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma, Blood, vol.102, issue.7, pp.2562-2569, 2003.
DOI : 10.1182/blood-2003-02-0493

S. Wuilleme, N. Robillard, L. Lode, F. Magrangeas, H. Beris et al., Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma, Leukemia, vol.19, issue.2, pp.275-283, 2005.
DOI : 10.1038/sj.leu.2403586

F. Cremer, J. Bila, I. Buck, M. Kartal, D. Hose et al., Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics, Genes, Chromosomes and Cancer, vol.40, issue.2, 2005.
DOI : 10.1002/gcc.20231

R. Garand, H. Avet-loiseau, F. Accard, P. Moreau, J. Harousseau et al., t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma, Leukemia, vol.17, issue.10, pp.2032-2037, 2003.
DOI : 10.1038/sj.leu.2403091

P. Moreau, T. Facon, X. Leleu, N. Morineau, P. Huyghe et al., Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy, Blood, vol.100, issue.5, pp.1579-83, 2002.
DOI : 10.1182/blood-2002-03-0749

M. Gertz, M. Lacy, A. Dispenzieri, P. Greipp, M. Litzow et al., Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy, Blood, vol.106, issue.8, 2005.
DOI : 10.1182/blood-2005-04-1411

P. Bergsagel, M. Chesi, E. Nardini, L. Brents, S. Kirby et al., Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma, Proceedings of the National Academy of Sciences, vol.86, issue.11, pp.13931-13936, 1996.
DOI : 10.1016/0092-8674(82)90137-4

M. Gertz, M. Lacy, A. Dispenzieri, P. Greipp, M. Litzow et al., Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy, Blood, vol.106, issue.8, 2005.
DOI : 10.1182/blood-2005-04-1411

N. Kroger, G. Schilling, H. Einsele, P. Liebisch, A. Shimoni et al., Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation, Blood, vol.103, issue.11, pp.4056-61, 2004.
DOI : 10.1182/blood-2003-12-4435

J. Drach, J. Ackermann, E. Fritz, E. Kromer, R. Schuster et al., Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy, Blood, vol.92, pp.802-809, 1998.

H. Chang, C. Qi, Q. Yi, D. Reece, and A. Stewart, p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation, Blood, vol.105, issue.1, pp.358-60, 2005.
DOI : 10.1182/blood-2004-04-1363

F. Zhan, J. Hardin, B. Kordsmeier, K. Bumm, M. Zheng et al., Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells, Blood, vol.99, issue.5, pp.1745-57, 2002.
DOI : 10.1182/blood.V99.5.1745

F. Zhan, E. Tian, K. Bumm, R. Smith, B. Barlogie et al., Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development, Blood, vol.101, issue.3, pp.1128-1168, 2003.
DOI : 10.1182/blood-2002-06-1737

J. Harousseau, J. Shaughnessy, J. Richardson, and P. , Multiple Myeloma, Hematology, vol.2004, issue.1, pp.237-56
DOI : 10.1182/asheducation-2004.1.237

URL : https://hal.archives-ouvertes.fr/inserm-00479729

M. Chesi, P. Bergsagel, and W. Kuehl, The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression, Current Opinion in Hematology, vol.9, issue.4, pp.288-93, 2002.
DOI : 10.1097/00062752-200207000-00005

M. Santra, F. Zhan, E. Tian, B. Barlogie, J. Shaughnessy et al., A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript, Blood, vol.101, issue.6, pp.2374-2380, 2003.
DOI : 10.1182/blood-2002-09-2801

P. Bergsagel, W. Kuehl, F. Zhan, J. Sawyer, B. Barlogie et al., Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma, Blood, vol.106, issue.1, pp.296-303, 2005.
DOI : 10.1182/blood-2005-01-0034

D. Hose, J. Rossi, C. Ittrich, J. Devos, A. Benner et al., A New Molecular Classification of Multiple Myeloma Using Gene Expression Profiling and Fluorescence In Situ Hybridisation as Predictor for Event Free Survival, Blood, vol.104, 2004.

J. Shaughnessy, J. Jacobson, J. Sawyer, J. Mccoy, A. Fassas et al., Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression, Blood, vol.101, issue.10, pp.3849-56, 2003.
DOI : 10.1182/blood-2002-09-2873

F. Cremer, D. Vos, J. Hose, D. Rossi, J. Ittrich et al., Multiple myeloma: global expression profiling indicates upregulation of the ribosomal machinery in hyperdiploid clones, Blood, vol.1004, p.1421, 2004.

P. Greipp, J. Katzmann, W. Fallon, and R. Kyle, Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma, pp.219-223, 1988.

Z. Gu, D. Vos, J. Rebouissou, C. , J. M. Zhang et al., Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors, Leukemia, vol.14, issue.1, pp.188-97, 2000.
DOI : 10.1038/sj.leu.2401632

B. Dankbar, T. Padro, R. Leo, B. Feldmann, M. Kropff et al., Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma, Blood, vol.95, pp.2630-2636, 2000.

A. Vacca, D. Ribatti, M. Presta, M. Minischetti, M. Iurlaro et al., Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma, Blood, vol.93, pp.3064-73, 1999.

H. Uchiyama, B. Barut, A. Mohrbacher, D. Chauhan, and K. Anderson, Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion, Blood, vol.82, pp.3712-3720, 1993.

T. Hideshima, D. Chauhan, P. Richardson, C. Mitsiades, N. Mitsiades et al., NF-??B as a Therapeutic Target in Multiple Myeloma, Journal of Biological Chemistry, vol.277, issue.19, pp.16639-16686, 2002.
DOI : 10.1074/jbc.M200360200

S. Yaccoby, M. Wezeman, A. Henderson, M. Cottler-fox, Q. Yi et al., Cancer and the Microenvironment: Myeloma-Osteoclast Interactions as a Model, Cancer Research, vol.64, issue.6, pp.2016-2039, 2004.
DOI : 10.1158/0008-5472.CAN-03-1131

E. Hurt, A. Wiestner, A. Rosenwald, A. Shaffer, E. Campo et al., Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma, Cancer Cell, vol.5, issue.2, pp.191-200, 2004.
DOI : 10.1016/S1535-6108(04)00019-4

V. Broek, I. Asosingh, K. Vanderkerken, K. Straetmans, N. et al., Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3, British Journal of Cancer, vol.88, issue.6, pp.855-62, 2003.
DOI : 10.1038/sj.bjc.6600833

M. Abe, K. Hiura, J. Wilde, K. Moriyama, T. Hashimoto et al., Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma, Blood, vol.100, pp.2195-202, 2002.

I. Van-riet, K. Vanderkerken, C. De-greef, and B. Van-camp, Homing behaviour of the malignant cell clone in multiple myeloma, Medical Oncology, vol.16, issue.3, pp.154-64, 1998.
DOI : 10.1007/BF02821934

V. Broek, I. Asosingh, K. Allegaert, V. Leleu, X. Facon et al., Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor, Leukemia, vol.18, issue.5, pp.976-82, 2004.
DOI : 10.1038/sj.leu.2403331

B. Klein, K. Tarte, M. Jourdan, K. Mathouk, J. Moreaux et al., Survival and Proliferation Factors of Normal and Malignant Plasma Cells, International Journal of Hematology, vol.276, issue.2, pp.106-113, 2003.
DOI : 10.1007/BF02983377

URL : https://hal.archives-ouvertes.fr/inserm-00130900

M. Kawano, T. Hirano, T. Matsuda, T. Taga, Y. Horii et al., Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas, Nature, vol.332, issue.6159, pp.83-85, 1988.
DOI : 10.1038/332083a0

B. Klein, X. Zhang, J. M. Content, J. Houssiau, F. Aarden et al., Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6, Blood, vol.73, pp.517-526, 1989.

M. Portier, G. Rajzbaum, X. Zhang, M. Attal, C. Rusalen et al., In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma, European Journal of Immunology, vol.76, issue.1, pp.1759-62, 1991.
DOI : 10.1002/eji.1830210727

B. Klein, J. M. , D. Vos, J. Mathouk, K. Moreaux et al., Survival and proliferation factors of human myeloma cells, Recent Advances in the Biology of Multiple Myeloma, 2003.

K. Mahtouk, J. M. , D. Vos, J. Hertogh, C. Fiol et al., An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis, Blood, vol.103, issue.5, pp.1829-1866, 2004.
DOI : 10.1182/blood-2003-05-1510

URL : https://hal.archives-ouvertes.fr/inserm-00130207

J. Moreaux, E. Legouffe, J. E. Quittet, P. Reme, T. Lugagne et al., BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone, Blood, vol.103, issue.8, pp.3148-57, 2004.
DOI : 10.1182/blood-2003-06-1984

URL : https://hal.archives-ouvertes.fr/inserm-00129502

Y. Wang, D. Vos, J. , J. M. Couderc, G. Lu et al., Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells, Oncogene, vol.21, issue.16, pp.2584-2592, 2002.
DOI : 10.1038/sj.onc.1205355

R. Harris, E. Chung, and R. Coffey, EGF receptor ligands, Experimental Cell Research, vol.284, issue.1, pp.2-13, 2003.
DOI : 10.1016/S0014-4827(02)00105-2

D. Graus-porta, R. Beerli, J. Daly, and N. Hynes, ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling, The EMBO Journal, vol.16, issue.7, pp.1647-55, 1997.
DOI : 10.1093/emboj/16.7.1647

K. Mahtouk, D. Hose, T. Reme, D. Vos, J. et al., Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells, Oncogene, vol.83, issue.21, pp.3512-3536, 2005.
DOI : 10.1038/sj.onc.1208536

URL : https://hal.archives-ouvertes.fr/inserm-00130206

B. Klein, D. Hose, K. Mahtouk, D. Vos, J. Reme et al., Identification of intercellular communication signals involved in multiple myeloma with microarrays, Haematologica/the hematology journal, vol.100, 2005.

Y. Qiu, L. Ravi, and H. Kung, Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells, Nature, vol.393, pp.83-88, 1998.

A. Badache and N. Hynes, Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells, Cancer Res, vol.61, pp.383-91, 2001.

D. Walters, J. French, B. Arendt, and D. Jelinek, Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-?? signaling complex, Oncogene, vol.22, issue.23, pp.3598-607, 2003.
DOI : 10.1038/sj.onc.1206512

J. Albanell and P. Gascon, Small Molecules with EGFR-TK Inhibitor Activity, Current Drug Targets, vol.6, issue.3, pp.259-74, 2005.
DOI : 10.2174/1389450053765888

A. Novak, J. Darce, B. Arendt, B. Harder, K. Henderson et al., Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival, Blood, vol.103, issue.2, pp.689-94, 2004.
DOI : 10.1182/blood-2003-06-2043

E. Tian, F. Zhan, R. Walker, E. Rasmussen, Y. Ma et al., The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma, New England Journal of Medicine, vol.349, issue.26, pp.2483-94, 2003.
DOI : 10.1056/NEJMoa030847

P. Derksen, E. Tjin, H. Meijer, M. Klok, H. Macgillavry et al., Illegitimate WNT signaling promotes proliferation of multiple myeloma cells, Proceedings of the National Academy of Sciences, vol.17, issue.4, pp.6122-6129, 2004.
DOI : 10.1038/sj.leu.2402875

D. Vos, J. Thykjaer-andersen, T. Tarte, K. Ensslen, M. Raynaud et al., Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays, Oncogene, vol.99, issue.44, pp.6848-6857, 2002.
DOI : 10.1038/sj.onc.1205868

M. Krampera, A. Pasini, A. Rigo, M. Scupoli, C. Tecchio et al., HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation, Blood, vol.106, issue.1, pp.59-66, 2005.
DOI : 10.1182/blood-2004-09-3645

L. Qin, J. Tamasi, L. Raggatt, X. Li, J. Feyen et al., Amphiregulin Is a Novel Growth Factor Involved in Normal Bone Development and in the Cellular Response to Parathyroid Hormone Stimulation, Journal of Biological Chemistry, vol.280, issue.5, pp.3974-81, 2005.
DOI : 10.1074/jbc.M409807200